160 related articles for article (PubMed ID: 1986238)
1. Mechanism of endogenous myc gene down-regulation in E mu-N-myc tumors.
Ma A; Smith RK; Tesfaye A; Achacoso P; Dildrop R; Rosenberg N; Alt FW
Mol Cell Biol; 1991 Jan; 11(1):440-4. PubMed ID: 1986238
[TBL] [Abstract][Full Text] [Related]
2. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice.
Möröy T; Verbeek S; Ma A; Achacoso P; Berns A; Alt F
Oncogene; 1991 Nov; 6(11):1941-8. PubMed ID: 1658705
[TBL] [Abstract][Full Text] [Related]
3. Expression of the c-myc oncogene under control of an immunoglobulin enhancer in E mu-myc transgenic mice.
Alexander WS; Schrader JW; Adams JM
Mol Cell Biol; 1987 Apr; 7(4):1436-44. PubMed ID: 3037318
[TBL] [Abstract][Full Text] [Related]
4. IgH enhancer-mediated deregulation of N-myc gene expression in transgenic mice: generation of lymphoid neoplasias that lack c-myc expression.
Dildrop R; Ma A; Zimmerman K; Hsu E; Tesfaye A; DePinho R; Alt FW
EMBO J; 1989 Apr; 8(4):1121-8. PubMed ID: 2501083
[TBL] [Abstract][Full Text] [Related]
5. Transformation of bone marrow cells from E mu-myc transgenic mice by Abelson murine leukemia virus and Harvey murine sarcoma virus.
Dyall-Smith D; Cory S
Oncogene Res; 1988 May; 2(4):403-9. PubMed ID: 2840624
[TBL] [Abstract][Full Text] [Related]
6. N-myc transgene promotes B lymphoid proliferation, elicits lymphomas and reveals cross-regulation with c-myc.
Rosenbaum H; Webb E; Adams JM; Cory S; Harris AW
EMBO J; 1989 Mar; 8(3):749-55. PubMed ID: 2785918
[TBL] [Abstract][Full Text] [Related]
7. H-2/myc, E mu/myc, and c-myc transgenic mice: potent sources of early hematopoietic cell lines.
Roland J; Morello D
Cell Growth Differ; 1993 Nov; 4(11):891-900. PubMed ID: 8297795
[TBL] [Abstract][Full Text] [Related]
8. An E mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene.
Rosenbaum H; Harris AW; Bath ML; McNeall J; Webb E; Adams JM; Cory S
EMBO J; 1990 Mar; 9(3):897-905. PubMed ID: 2155783
[TBL] [Abstract][Full Text] [Related]
9. Functional homology between N-myc and c-myc in murine plasmacytomagenesis: plasmacytoma development in N-myc transgenic mice.
Wang Y; Sugiyama H; Axelson H; Panda CK; Babonits M; Ma A; Steinberg JM; Alt FW; Klein G; Wiener F
Oncogene; 1992 Jun; 7(6):1241-7. PubMed ID: 1375720
[TBL] [Abstract][Full Text] [Related]
10. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
11. Increased transcription of the E mu-myc transgene and mRNA stabilisation produce only a modest elevation in Myc protein.
Colley SM; Tilbrook PA; Klinken SP
Oncogene; 1997 Jun; 14(22):2735-9. PubMed ID: 9178772
[TBL] [Abstract][Full Text] [Related]
12. A human immunoglobulin gene reduces the incidence of lymphomas in c-Myc-bearing transgenic mice.
Nussenzweig MC; Schmidt EV; Shaw AC; Sinn E; Campos-Torres J; Mathey-Prevot B; Pattengale PK; Leder P
Nature; 1988 Dec; 336(6198):446-50. PubMed ID: 3143076
[TBL] [Abstract][Full Text] [Related]
13. IgH enhancer deregulated expression of L-myc: abnormal T lymphocyte development and T cell lymphomagenesis.
Möröy T; Fisher P; Guidos C; Ma A; Zimmerman K; Tesfaye A; DePinho R; Weissman I; Alt FW
EMBO J; 1990 Nov; 9(11):3659-66. PubMed ID: 2120050
[TBL] [Abstract][Full Text] [Related]
14. MHC class I expression on prelymphomatous and lymphomatous B-cells is not inhibited by an E mu-myc transgene.
Algarra I; Silva S; Ljunggren HG
Eur J Cancer; 1993; 29A(2):238-41. PubMed ID: 8422288
[TBL] [Abstract][Full Text] [Related]
15. Surface IgM mediated regulation of RAG gene expression in E mu-N-myc B cell lines.
Ma A; Fisher P; Dildrop R; Oltz E; Rathbun G; Achacoso P; Stall A; Alt FW
EMBO J; 1992 Jul; 11(7):2727-34. PubMed ID: 1628630
[TBL] [Abstract][Full Text] [Related]
16. High frequency of myelomonocytic tumors in aging E mu L-myc transgenic mice.
Möröy T; Fisher PE; Lee G; Achacoso P; Wiener F; Alt FW
J Exp Med; 1992 Feb; 175(2):313-22. PubMed ID: 1310099
[TBL] [Abstract][Full Text] [Related]
17. 1,25-Dihydroxyvitamin D3 regulation of c-myc protooncogene transcription. Possible involvement of protein kinase C.
Simpson RU; Hsu T; Wendt MD; Taylor JM
J Biol Chem; 1989 Nov; 264(33):19710-5. PubMed ID: 2684961
[TBL] [Abstract][Full Text] [Related]
18. The transgenic window on lymphoid malignancy.
Adams JM; Harris AW; Vaux DL; Alexander WS; Rosenbaum H; Klinken SP; Strasser A; Bath ML; McNeall J; Cory S
Princess Takamatsu Symp; 1989; 20():297-309. PubMed ID: 2518688
[TBL] [Abstract][Full Text] [Related]
19. Multiple mechanisms of tumorigenesis in E mu-myc transgenic mice.
Sidman CL; Denial TM; Marshall JD; Roths JB
Cancer Res; 1993 Apr; 53(7):1665-9. PubMed ID: 8453639
[TBL] [Abstract][Full Text] [Related]
20. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
